Evaluation of Serum Level of Insulin Like Growth Factor 1NCT05301569
Relation Between Serum IGF-1 & BMI In Acne Vulgaris
An observational study of Evaluation of Serum Level of Insulin Like Growth Factor 1, run by Assiut University at 1 site in Egypt.
Trial summary
cross-sectional study in which participants will be recruited at dermatology \& Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists \& obtaining an informed consent Read more about this study
- Who is it for?
- Ages 15 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Evaluation of Serum Level of Insulin Like Growth Factor 1
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2023to 30 May 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 45 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Acne vulgaris patients aged from 15 to 45 years old
Who may be able to join
- Patients aged from 15 to 45 years old suffering from acne vulgaris.
- Both sexes.
Who cannot join
- Insulin resistance and diabetic patients
- Females with polycystic ovarian syndrome
- Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study.
- Other causes of acne or acneform eruption as steroid-induced
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Rania Sallam
Cairo, Qalubya, 13772
Rania Sallam, 113567939, Raniamohamed0887@gmail.com
About this study
Official title: Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris
cross-sectional study in which participants will be recruited at dermatology \& Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists \& obtaining an informed consent
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of serum level of insulin like growth factor 1 in acne vulgaris
using the Chemiluminescent Microparticle Immunoassay
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2022
- Study start1 Apr 2023
- Primary completion30 May 2024 (estimated)
- Study completion30 May 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Evaluation of Serum Level of Insulin Like Growth Factor 1Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rania Sallam Mohamed Taha, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05301569
- Sponsor's protocol ID
- IGF-1 in AV
- Status last verified
- Dec 2023
- First submitted
- 16 Mar 2022
- Last updated
- 5 Dec 2023
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris
- ClinicalTrials.gov ID
- NCT05301569
- Acronym / sponsor ID
- IGF-1 in AV
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Apr 2023 (actual)
- Primary completion
- 30 May 2024 (estimated)
- Study completion
- 30 May 2024 (estimated)
- First posted
- 29 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
cross-sectional study in which participants will be recruited at dermatology \& Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists \& obtaining an informed consent
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 15 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Acne vulgaris patients aged from 15 to 45 years old
Key inclusion criteria (2 listed)
- Patients aged from 15 to 45 years old suffering from acne vulgaris.
- Both sexes.
Key exclusion criteria (4 listed)
- Insulin resistance and diabetic patients
- Females with polycystic ovarian syndrome
- Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study.
- Other causes of acne or acneform eruption as steroid-induced
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of serum level of insulin like growth factor 1 in acne vulgaris
Time frame: 1 year
using the Chemiluminescent Microparticle Immunoassay
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2023.
Related trials for Evaluation of Serum Level of Insulin Like Growth Factor 1
Active, not recruitingObservational study
Serum IGF-1 and IGF-1Ec in Malignancy Assessment
Cancer, Solid Tumor Malignancies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Evaluation of Serum Level of Insulin Like Growth Factor 1, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rania Sallam (113567939, Raniamohamed0887@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of serum level of insulin like growth factor 1 in acne vulgaris (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2023.